. (2024). The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis. Health Soc Care Deliv Res, 12, 1-275. http://doi.org/10.3310/kltr7714
*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
. (2023). Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the CPRD. Bmj Open, 13, e064541. http://doi.org/10.1136/bmjopen-2022-064541
. (2022). Association between continuity of primary care and both prescribing and adherence of common cardiovascular medications: a cohort study among patients in England. Bmj Open, 12, e063282. http://doi.org/10.1136/bmjopen-2022-063282